risedronate   

GtoPdb Ligand ID: 3176

Synonyms: Actonel® | Atelvia® | NE-58095 | risedronate sodium
risedronate is an approved drug (FDA (1998))
Compound class: Synthetic organic
Comment: Risedronate is a bisphosphonate drug.
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: risedronate

2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 5
Rotatable bonds 4
Topological polar surface area 167.8
Molecular weight 283
XLogP -3.62
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Canonical SMILES OP(=O)(C(P(=O)(O)O)(Cc1cccnc1)O)O
Isomeric SMILES OP(=O)(C(P(=O)(O)O)(Cc1cccnc1)O)O
InChI InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15)
InChI Key IIDJRNMFWXDHID-UHFFFAOYSA-N
References
1. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. (2000)
Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
Arch. Biochem. Biophys., 373 (1): 231-41. [PMID:10620343]
2. Dunford JE, Kwaasi AA, Rogers MJ, Barnett BL, Ebetino FH, Russell RG, Oppermann U, Kavanagh KL. (2008)
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
J. Med. Chem., 51 (7): 2187-95. [PMID:18327899]
3. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ. (2001)
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
J. Pharmacol. Exp. Ther., 296 (2): 235-42. [PMID:11160603]